Furthermore, AIB1 overexpression has been associated with tamoxifen resistance in hormone-responsive HER2+ breast cancers, suggesting that AIB1 could be a potential therapeutic target (Osborne et al. 2003, Kirkegaard et al. 2007). Here, ERBB2 is linked to breast cancer.